Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2022-11-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-11-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 October 2022. It details movements in authorized and issued share capital, share options, convertibles, and other share-related information. It is submitted to the Hong Kong Exchanges and Clearing Limited and includes detailed tables on share capital and movements. The document is a regulatory filing related to share capital movements and does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report but a regulatory return. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about share capital and securities movements under exchange rules.
2022-11-03 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-11-02 English
UPDATE ANNOUNCEMENT IN RELATION TO CONNECTED TRANSACTION OF INVESTMENT IN THE KANGJUN ZHONGYUAN FUND
Capital/Financing Update Classification · 95% confidence The document is an announcement from Pharmaron Beijing Co., Ltd. regarding an update to a connected transaction related to an investment in the Kangjun Zhongyuan Fund. It references a previous announcement dated August 12, 2021, and provides detailed information about amendments to the limited partnership agreement, including changes in the fund size, subscription period, and admission of new limited partners. The document includes detailed financial commitments by partners and clarifies the connected persons involved. The content is focused on providing an update on a specific financing/investment transaction rather than presenting a full financial report or earnings results. It is not a full annual or interim report, audit report, earnings release, or management discussion. It is also not a regulatory filing or certification. The document is an update announcement related to a capital investment transaction, fitting the category of Capital/Financing Update (CAP). The document length is over 10,000 characters, indicating it is a substantive announcement rather than a brief notice or report publication announcement.
2022-10-28 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-10-27 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-10-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.